Life Sciences Tools and Services
Company Overview of M3 Biotechnology, Inc.
M3 Biotechnology, Inc. develops a knowledge-based discovery platform to identify novel small molecules that control protein growth factor multimerization, an approach in drugging protein-protein interactions. The company focuses on therapeutic programs for Parkinson’s and Alzheimer’s disease, and age-related dementia. Its pipeline product includes MM-201, an orally available, blood brain barrier permeate and disease-modifying treatment for Parkinson’s and Alzheimer’s diseases. The company was founded in 2011 and is based in Seattle, Washington.
4000 Mason Road
Seattle, WA 98195-2141
Founded in 2011
Key Executives for M3 Biotechnology, Inc.
M3 Biotechnology, Inc. Key Developments
Similar Private Companies By Industry
|10X Genomics, Inc.||United States|
|4G Clinical, Inc.||United States|
|AAPharmaSyn LLC||United States|
|Abiant, Inc.||United States|
|aBioBot, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact M3 Biotechnology, Inc., please visit www.m3bio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.